IMU

2.08%

4.9¢ imugene limited

Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-82

First 82 Last

Share
Profile

Follow
AlCp

27,422 Posts.

1781

17/01/24

14:25

Post #: 71924179
Share

Originally posted by nayr ↑

Does anyone else have difficulty when trying to interpret the results of clinical trials as reported by IMU?

The data looks good from what I can interpret, but if they could present it with more clarity and structure then I’m sure it would become even more enlightening for shareholders and others.

We know that in relation to the MAST trial: CF33-hNIS is administered alone, or in combination with pembrolizumab and either dosed intravenously (IV) or intratumourally (IT). But do we really know for example how many patients treated with pembro intratumourally have had a partial response?

We know that: As of 12 January 2024, 38 patients have been dosed with VAXINIA during the continuing dose escalation phase, comprised of 19 patients dosed intratumourally and 19 patients dosed intravenously as either monotherapy or in combination with pembrolizumab. And that: 31 patients were evaluable for efficacy (received at least their first scan at day 42).

But it does get a bit messy.

In the IT cohorts (14 patients), 7 of 15 (47%) [should this be 7 of 14 (50%)?] injected lesions had a reduction in tumour burden [so Partial Response?], 3 lesions were completely eradicated [so Complete Response?].

The report then goes on to state that: 3 patients (21%) had an objective response [Objective response defined as patients with a complete or partial response; 1 complete response by iRECIST in a patient with cholangiocarcinoma (a type of biliary tract cancer); and 2 partial responses in patients with melanoma (skin cancer) by RECIST.

So we have this: 7 lesions with a reduction in tumour burden; 3 lesions completely eradicated; 3 patients with an OR; 1 CR; and 2 PR. The numbers don’t compute or must include some double counting.

It is a bit clearer for IV cohorts: 17 patients, 53% of patients [Must be 9 patients] achieved stable disease as their best response.

Then later: 7 patients with gastrointestinal cancers who received CF33-hNIS alone including 3 colorectal, 2 biliary tract, 1 pancreatic and 1 liver cancer showed positive treatment effects, with a disease control rate (all CR, PR and SD) of 86%. How is the 86% calculated? [7 patients out of 8 = 87.5%] We know from the above information that there were 2 non-gastro PR (melanomas) so again the numbers don’t compute.

It would be nice to know exactly how many CR + PR+ SD we have as a result of this study and how they are categorized by IV or IT and mono or pembro and by type of cancer.

I’m sure that some of our brightest contributors can help clarify.

Expand

The market did respond to 12c and then got bonked again back to 10.5c.

IMU Price at posting: 10.5¢ Sentiment: None Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

TIG

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

SHN

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

NWH

NRW Holdings inks $109M deal with BHP for works at Jimblebar

CXU

Cauldron Energy reports "excellent" uranium assays in latest drill run

IMA

Issues emerging as Australian companies tackle critical minerals challenge

RAG

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

A3D

Defence MOU for propulsion systems pushes Aurora Lab shares higher

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

There are more pages in this discussion • 96 more messages in this thread...

First 82 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.9¢		Change 0.001(2.08%)		Mkt cap ! $364.4M

Open	High	Low	Value	Volume
4.8¢	4.9¢	4.8¢	$179.8K	3.692M

Buyers (Bids)

No.	Vol.	Price($)
62	8124186	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	3070575	9

View Market Depth

No.	Vol.	Price($)
56	7804777	0.048
47	5437350	0.047
38	3197542	0.046
58	3766545	0.045
11	1019564	0.044

Price($)	Vol.	No.
0.049	2050167	7
0.050	5223480	23
0.051	4434080	10
0.052	2536519	9
0.053	1966973	9

Last trade - 16.10pm 11/10/2024 (20 minute delay)

IMU (ASX) Chart

Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-82

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Cauldron Energy reports "excellent" uranium assays in latest drill run

Issues emerging as Australian companies tackle critical minerals challenge

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Defence MOU for propulsion systems pushes Aurora Lab shares higher

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-82

Top Stories

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Cauldron Energy reports "excellent" uranium assays in latest drill run

Issues emerging as Australian companies tackle critical minerals challenge

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Defence MOU for propulsion systems pushes Aurora Lab shares higher

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News